Literature DB >> 24747619

Giant cell tumors of bone: nonsurgical factors associated with local recurrence.

Luiz Eduardo Moreira Teixeira1, José Carlos Souza Vilela2, Ricardo Horta Miranda3, Anderson Humberto Gomes4, Frederico Alves Costa4, Vinicius Carvalho de Faria4.   

Abstract

OBJECTIVE: To determine the rate of giant cell tumor (GCT) recurrence and evaluate the factors associated with its recurrence in patients who underwent surgery and submitted to only one adjuvant method.
METHODS: Forty-one patients (22 female, 19 male; mean age: 34.22 ± 9.70 years) with GCT, who underwent surgical and one adjuvant treatment, were evaluated after a mean follow-up period of 40.17 ± 22.08 months. The average tumor size was 8.51 ± 3.69 cm. The tumors in 18 patients (43.9%) were grade II and in 23 patients (56.1%) grade III, according to the system developed by Campanacci et al. The surgical margin was intralesional resection and curettage in 60.9% of the patients, and marginal or wide resection in 39.1%.
RESULTS: Nine (22%) of the 41 patients had recurrence. None of the gender (p=0.436), age (p=0.310), site of the tumor (p=0.940), surgical margins (p=0.400) and the type of the filling material (PMMA or autograft) (p=0.680) had an association with recurrence. However, Campanacci grade III (p=0.028) and the size of the tumor (p=0.034) was associated with the recurrence.
CONCLUSION: Tumor size and tumor grade III according to the Campanacci system appear to be risk factors for local recurrence after the local resection of GCT.

Entities:  

Mesh:

Year:  2014        PMID: 24747619     DOI: 10.3944/AOTT.2014.2714

Source DB:  PubMed          Journal:  Acta Orthop Traumatol Turc        ISSN: 1017-995X            Impact factor:   1.511


  8 in total

Review 1.  Prognosis of local recurrence in giant cell tumour of bone: what can we do?

Authors:  Yifeng He; Ji Zhang; Xiaoyi Ding
Journal:  Radiol Med       Date:  2017-03-07       Impact factor: 3.469

2.  A prospective study on predicting local recurrence of giant cell tumour of bone by evaluating preoperative imaging features of the tumour around the knee joint.

Authors:  Yifeng He; Jun Wang; Ji Zhang; Fei Yuan; Xiaoyi Ding
Journal:  Radiol Med       Date:  2017-03-07       Impact factor: 3.469

Review 3.  RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.

Authors:  Pan-Feng Wu; Ju-yu Tang; Kang-hua Li
Journal:  Tumour Biol       Date:  2015-01-25

4.  Mid-term results of intralesional extended curettage, cauterization, and polymethylmethacrylate cementation in the treatment of giant cell tumor of bone: A retrospective case series.

Authors:  Evrim Şirin; Ahmet Hamdi Akgülle; Osman Mert Topkar; Ömer Sofulu; Said Erkam Baykan; Bülent Erol
Journal:  Acta Orthop Traumatol Turc       Date:  2020-09       Impact factor: 1.511

5.  Magnetic resonance feature of "paintbrush borders" sign as a novel way to predict recurrence of giant cell tumor of bone after curettage: a pilot study.

Authors:  Yifeng He; Jun Wang; Ji Zhang; Lianjun Du; Yong Lu; Jianqiang Xu; Fei Yuan; Yimin Tan; Xiaoyi Ding
Journal:  J Int Med Res       Date:  2017-09-12       Impact factor: 1.671

6.  Epidemiologic Characteristics, Clinical Behavior, and Outcome of the Giant Cell Tumor of the Bone: A Retrospective Single-center Study.

Authors:  Khodamorad Jamshidi; Amin Karimi; Alireza Mirzaei
Journal:  Arch Bone Jt Surg       Date:  2019-11

7.  Managements of giant cell tumor within the distal radius: A retrospective study of 58 cases from a single center.

Authors:  Changye Zou; Tiao Lin; Bo Wang; Zhiqiang Zhao; Bin Li; Xianbiao Xie; Gang Huang; Junqiang Yin; Jingnan Shen
Journal:  J Bone Oncol       Date:  2018-12-14       Impact factor: 4.072

8.  Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.

Authors:  Wangqiang Jia; Long Yuan; Hongyan Ni; Benling Xu; Peng Zhao
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.